Symbols / IOVA $3.99 -1.24%
IOVA Chart
About
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.64B |
| Enterprise Value | 1.42B | Income | -390.98M | Sales | 263.50M |
| Book/sh | 1.70 | Cash/sh | 0.72 | Dividend Yield | — |
| Payout | 0.00% | Employees | 975 | IPO | — |
| P/E | — | Forward P/E | -16.56 | PEG | — |
| P/S | 6.24 | P/B | 2.35 | P/C | — |
| EV/EBITDA | -3.91 | EV/Sales | 5.38 | Quick Ratio | 2.74 |
| Current Ratio | 3.20 | Debt/Eq | 7.08 | LT Debt/Eq | — |
| EPS (ttm) | -1.09 | EPS next Y | -0.24 | EPS Growth | — |
| Revenue Growth | 17.70% | Earnings | 2026-05-07 | ROA | -27.30% |
| ROE | -55.50% | ROIC | — | Gross Margin | 34.28% |
| Oper. Margin | -84.66% | Profit Margin | -148.38% | Shs Outstand | 411.96M |
| Shs Float | 353.41M | Short Float | 34.19% | Short Ratio | 8.93 |
| Short Interest | — | 52W High | 5.63 | 52W Low | 1.64 |
| Beta | 0.74 | Avg Volume | 15.39M | Volume | 3.52M |
| Target Price | $9.00 | Recom | Buy | Prev Close | $4.04 |
| Price | $3.99 | Change | -1.24% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.00
Mean price target
2. Current target
$4.01
Latest analyst target
3. DCF / Fair value
$-7.10
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.01
Low
$4.00
High
$16.00
Mean
$9.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-05 | main | UBS | Neutral → Neutral | $4 |
| 2026-03-03 | up | Citizens | Market Perform → Market Outperform | $5 |
| 2026-02-25 | main | Barclays | Overweight → Overweight | $11 |
| 2026-02-25 | up | Citizens | Market Perform → Market Outperform | $5 |
| 2025-12-17 | main | Barclays | Overweight → Overweight | $10 |
| 2025-11-24 | main | Barclays | Overweight → Overweight | $9 |
| 2025-11-06 | main | Chardan Capital | Buy → Buy | $17 |
| 2025-10-29 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-08-19 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-08-08 | main | Wells Fargo | Overweight → Overweight | $14 |
| 2025-08-08 | main | Chardan Capital | Buy → Buy | $20 |
| 2025-07-23 | main | Chardan Capital | Buy → Buy | $25 |
| 2025-05-16 | down | UBS | Buy → Neutral | $2 |
| 2025-05-12 | main | Goldman Sachs | Buy → Buy | $8 |
| 2025-05-12 | main | Mizuho | Outperform → Outperform | $10 |
| 2025-05-12 | main | Barclays | Overweight → Overweight | $4 |
| 2025-05-09 | down | JMP Securities | Market Outperform → Market Perform | — |
| 2025-05-09 | main | Chardan Capital | Buy → Buy | $25 |
| 2025-05-09 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-04-17 | main | Goldman Sachs | Buy → Buy | $16 |
- Long Focus Capital Management LLC Reduces Stock Position in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat ue, 17 Mar 2026 12
- Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - The Motley Fool hu, 05 Mar 2026 08
- Iovance Biotherapeutics Inc (IOVA) Stock Price, Trades & News - GuruFocus hu, 12 Mar 2026 00
- After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits Wed, 25 Feb 2026 06
- Is Iovance Biotherapeutics Inc. (IOVA) One of the Best Immunotherapy Stocks to Buy According to Hedge Funds? - Yahoo Finance hu, 19 Feb 2026 08
- A Look At Iovance Biotherapeutics (IOVA) Valuation After Sharp Recent Share Price Momentum - simplywall.st ue, 10 Mar 2026 05
- Inside Iovance: 30% Q4 sales jump and FDA Fast Track for lung cancer TIL - Stock Titan ue, 24 Feb 2026 08
- Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain - I'm Still Bullish After All These Years - Seeking Alpha Wed, 04 Mar 2026 08
- Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.5% - What's Next? - MarketBeat Wed, 11 Mar 2026 19
- One-time cell therapy shrinks tough sarcomas in early Iovance trial - Stock Titan ue, 24 Feb 2026 08
- IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits hu, 05 Mar 2026 06
- Is It Too Late To Reassess Iovance Biotherapeutics (IOVA) After Its Recent Share Price Surge - simplywall.st Sun, 08 Mar 2026 08
- 1 Nearly Unknown Biotech Stock Set To Go Parabolic If Its Pipeline Hits - The Motley Fool Mon, 23 Feb 2026 08
- Why Iovance Biotherapeutics (IOVA) Is Up 12.5% After Amtagvi-Fueled Q4 Beat And Narrower Loss - Yahoo Finance ue, 24 Feb 2026 08
- Why 2 Small Biotechs May Hold the Key to New Cancer Treatments - MarketBeat hu, 12 Mar 2026 19
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 31246 | — | — | GRAF FINCKENSTEIN FRIEDRICH | Officer | — | 2026-03-05 00:00:00 | D | nan |
| 1 | 39059 | — | — | PURI RAJ K | Officer | — | 2026-03-05 00:00:00 | D | nan |
| 2 | 31246 | — | — | BILINSKY IGOR P | Chief Operating Officer | — | 2026-03-05 00:00:00 | D | nan |
| 3 | 62493 | — | — | VOGT FREDERICK G | Chief Executive Officer | — | 2026-03-05 00:00:00 | D | nan |
| 4 | 12697 | — | — | GRAF FINCKENSTEIN FRIEDRICH | Officer | — | 2026-03-02 00:00:00 | D | nan |
| 5 | 5470 | — | — | PURI RAJ K | Officer | — | 2026-03-02 00:00:00 | D | nan |
| 6 | 12307 | — | — | BILINSKY IGOR P | Chief Operating Officer | — | 2026-03-02 00:00:00 | D | nan |
| 7 | 52087 | — | — | VOGT FREDERICK G | Chief Executive Officer | — | 2026-03-02 00:00:00 | D | nan |
| 8 | 120000 | — | — | KIRBY DANIEL GORDON | Officer | — | 2026-02-24 00:00:00 | D | nan |
| 9 | 39996 | — | — | KIRBY DANIEL GORDON | Officer | — | 2026-02-10 00:00:00 | D | nan |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -27.26K | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.01 | 0.01 | 0.01 | 0.00 |
| NormalizedEBITDA | -345.75M | -347.21M | -427.43M | -377.74M |
| TotalUnusualItems | -5.14M | 0.00 | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | -5.14M | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -390.98M | -372.18M | -444.04M | -395.89M |
| ReconciledDepreciation | 47.32M | 48.07M | 33.13M | 21.14M |
| ReconciledCostOfRevenue | 161.80M | 82.78M | 10.76M | 0.00 |
| EBITDA | -350.89M | -347.21M | -427.43M | -377.74M |
| EBIT | -398.21M | -395.28M | -460.56M | -398.88M |
| NetInterestIncome | 10.31M | 20.27M | 13.04M | 2.98M |
| InterestIncome | 10.31M | 20.27M | 13.04M | 2.98M |
| NormalizedIncome | -385.86M | -372.18M | -444.04M | -395.89M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -390.98M | -372.18M | -444.04M | -395.89M |
| TotalExpenses | 661.72M | 559.35M | 461.75M | 398.88M |
| TotalOperatingIncomeAsReported | -403.36M | -395.28M | -460.56M | -398.88M |
| DilutedAverageShares | 357.35M | 289.88M | 235.13M | 159.26M |
| BasicAverageShares | 357.35M | 289.88M | 235.13M | 159.26M |
| DilutedEPS | -1.09 | -1.28 | -1.89 | -2.49 |
| BasicEPS | -1.09 | -1.28 | -1.89 | -2.49 |
| DilutedNIAvailtoComStockholders | -390.98M | -372.18M | -444.04M | -395.89M |
| NetIncomeCommonStockholders | -390.98M | -372.18M | -444.04M | -395.89M |
| NetIncome | -390.98M | -372.18M | -444.04M | -395.89M |
| NetIncomeIncludingNoncontrollingInterests | -390.98M | -372.18M | -444.04M | -395.89M |
| NetIncomeContinuousOperations | -390.98M | -372.18M | -444.04M | -395.89M |
| TaxProvision | -2.07M | -2.83M | -3.48M | 0.00 |
| PretaxIncome | -393.05M | -375.00M | -447.52M | -395.89M |
| OtherIncomeExpense | -5.14M | |||
| SpecialIncomeCharges | -5.14M | 0.00 | 0.00 | |
| RestructuringAndMergernAcquisition | 5.14M | 0.00 | 0.00 | |
| NetNonOperatingInterestIncomeExpense | 10.31M | 20.27M | 13.04M | 2.98M |
| InterestIncomeNonOperating | 10.31M | 20.27M | 13.04M | 2.98M |
| OperatingIncome | -398.21M | -395.28M | -460.56M | -398.88M |
| OperatingExpense | 488.53M | 466.10M | 450.99M | 398.88M |
| DepreciationAmortizationDepletionIncomeStatement | 35.94M | 37.60M | 21.42M | |
| DepreciationAndAmortizationInIncomeStatement | 35.94M | 37.60M | 21.42M | |
| ResearchAndDevelopment | 300.27M | 276.23M | 344.08M | 294.78M |
| SellingGeneralAndAdministration | 152.32M | 152.27M | 106.92M | 104.10M |
| GeneralAndAdministrativeExpense | 104.10M | 83.66M | ||
| OtherGandA | 104.10M | 83.66M | ||
| GrossProfit | 90.32M | 70.82M | -9.57M | 0.00 |
| CostOfRevenue | 173.18M | 93.25M | 10.76M | 0.00 |
| TotalRevenue | 263.50M | 164.07M | 1.19M | 0.00 |
| OperatingRevenue | 268.00M | 169.17M | 1.19M | 0.00 |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 411.94M | 305.25M | 256.14M | 187.81M |
| ShareIssued | 411.94M | 305.25M | 256.14M | 187.81M |
| TotalDebt | 49.44M | 58.26M | 75.86M | 85.45M |
| TangibleBookValue | 419.26M | 428.00M | 355.35M | 499.63M |
| InvestedCapital | 699.58M | 711.40M | 585.61M | 500.63M |
| WorkingCapital | 304.33M | 334.68M | 197.54M | 387.63M |
| NetTangibleAssets | 419.26M | 428.01M | 355.36M | 499.64M |
| CapitalLeaseObligations | 48.44M | 57.26M | 74.86M | 84.45M |
| CommonStockEquity | 698.58M | 710.40M | 584.61M | 499.63M |
| PreferredStockEquity | 2.00K | 3.00K | 3.00K | 3.00K |
| TotalCapitalization | 698.58M | 711.40M | 585.61M | 500.64M |
| TotalEquityGrossMinorityInterest | 698.58M | 710.40M | 584.61M | 499.64M |
| StockholdersEquity | 698.58M | 710.40M | 584.61M | 499.64M |
| GainsLossesNotAffectingRetainedEarnings | 16.44M | -1.05M | 2.53M | -902.00K |
| OtherEquityAdjustments | 16.44M | -1.05M | 2.53M | -902.00K |
| RetainedEarnings | -2.78B | -2.38B | -2.01B | -1.57B |
| AdditionalPaidInCapital | 3.46B | 3.10B | 2.59B | 2.07B |
| CapitalStock | 19.00K | 16.00K | 14.00K | 11.00K |
| CommonStock | 17.00K | 13.00K | 11.00K | 8.00K |
| PreferredStock | 2.00K | 3.00K | 3.00K | 3.00K |
| TotalLiabilitiesNetMinorityInterest | 214.59M | 200.02M | 195.74M | 164.34M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 76.23M | 77.68M | 85.43M | 72.86M |
| NonCurrentDeferredLiabilities | 31.83M | 32.31M | 17.35M | 0.00 |
| NonCurrentDeferredTaxesLiabilities | 31.83M | 32.31M | 17.35M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 44.40M | 45.37M | 68.08M | 72.86M |
| LongTermCapitalLeaseObligation | 44.40M | 44.37M | 67.08M | 71.86M |
| LongTermDebt | 1.00M | 1.00M | 1.00M | 1.00M |
| CurrentLiabilities | 138.36M | 122.34M | 110.31M | 91.48M |
| CurrentDebtAndCapitalLeaseObligation | 5.04M | 12.90M | 7.78M | 12.59M |
| CurrentCapitalLeaseObligation | 4.04M | 12.90M | 7.78M | 12.59M |
| CurrentDebt | 1.00M | |||
| CurrentNotesPayable | 1.00M | 0.00 | ||
| PayablesAndAccruedExpenses | 133.31M | 109.44M | 102.53M | 78.90M |
| CurrentAccruedExpenses | 111.16M | 81.94M | 69.41M | 52.30M |
| Payables | 22.16M | 27.51M | 33.12M | 26.60M |
| AccountsPayable | 22.16M | 27.51M | 33.12M | 26.60M |
| TotalAssets | 913.17M | 910.43M | 780.35M | 663.98M |
| TotalNonCurrentAssets | 470.48M | 453.41M | 472.50M | 184.87M |
| OtherNonCurrentAssets | 14.15M | 6.73M | 66.70M | 6.62M |
| InvestmentsAndAdvances | 0.00 | 91.59M | ||
| InvestmentinFinancialAssets | 0.00 | 91.59M | ||
| AvailableForSaleSecurities | 91.59M | |||
| GoodwillAndOtherIntangibleAssets | 279.32M | 282.40M | 229.26M | 0.00 |
| NetPPE | 177.01M | 164.28M | 176.54M | 178.25M |
| AccumulatedDepreciation | -48.77M | -36.02M | -27.91M | -16.72M |
| GrossPPE | 225.78M | 200.30M | 204.46M | 194.97M |
| Leases | 90.39M | 67.38M | 76.80M | 74.31M |
| ConstructionInProgress | 35.65M | 34.94M | 24.10M | 9.12M |
| OtherProperties | 84.70M | 86.67M | 91.64M | 101.10M |
| MachineryFurnitureEquipment | 15.04M | 11.32M | 11.92M | 10.44M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 442.69M | 457.02M | 307.85M | 479.12M |
| OtherCurrentAssets | 11.58M | 12.38M | 17.46M | 7.27M |
| PrepaidAssets | 3.55M | |||
| Inventory | 51.68M | 51.52M | 10.37M | 0.00 |
| OtherInventories | -7.88M | |||
| FinishedGoods | 22.83M | 15.01M | 4.62M | 0.00 |
| WorkInProcess | 5.04M | 8.77M | 5.75M | 0.00 |
| RawMaterials | 31.68M | 27.74M | 0.00 | |
| Receivables | 82.45M | 69.34M | 151.00K | 0.00 |
| AccountsReceivable | 82.45M | 69.34M | 151.00K | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 296.98M | 323.78M | 279.87M | 471.85M |
| OtherShortTermInvestments | 133.90M | 208.09M | 164.98M | 240.11M |
| CashAndCashEquivalents | 163.08M | 115.69M | 114.89M | 231.73M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -336.24M | -364.05M | -384.11M | -313.18M |
| IssuanceOfDebt | 0.00 | 0.00 | 1.00M | |
| IssuanceOfCapitalStock | 306.31M | 397.30M | 463.28M | 189.50M |
| CapitalExpenditure | -33.84M | -11.07M | -22.29M | -20.43M |
| EndCashPosition | 169.06M | 122.05M | 181.32M | 238.16M |
| BeginningCashPosition | 122.05M | 181.32M | 238.16M | 84.31M |
| EffectOfExchangeRateChanges | 1.14M | -541.00K | -2.74M | |
| ChangesInCash | 45.86M | -58.72M | -54.10M | 153.85M |
| FinancingCashFlow | 300.77M | 390.66M | 462.96M | 190.15M |
| CashFlowFromContinuingFinancingActivities | 300.77M | 390.66M | 462.96M | 190.15M |
| NetOtherFinancingCharges | -7.06M | -12.86M | -2.79M | -2.65M |
| ProceedsFromStockOptionExercised | 1.52M | 6.22M | 2.47M | 3.30M |
| NetCommonStockIssuance | 306.31M | 397.30M | 463.28M | 189.50M |
| CommonStockIssuance | 306.31M | 397.30M | 463.28M | 189.50M |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | 1.00M | |
| NetLongTermDebtIssuance | 0.00 | 0.00 | 1.00M | |
| LongTermDebtIssuance | 0.00 | 0.00 | 1.00M | |
| InvestingCashFlow | 47.50M | -96.41M | -155.24M | 256.45M |
| CashFlowFromContinuingInvestingActivities | 47.50M | -96.41M | -155.24M | 256.45M |
| NetInvestmentPurchaseAndSale | 81.33M | -32.77M | 79.68M | 276.88M |
| SaleOfInvestment | 400.00M | 428.00M | 285.58M | 522.70M |
| PurchaseOfInvestment | -318.67M | -460.77M | -205.90M | -245.82M |
| NetBusinessPurchaseAndSale | 0.00 | -52.57M | -212.63M | 0.00 |
| PurchaseOfBusiness | 0.00 | -52.57M | -212.63M | 0.00 |
| NetPPEPurchaseAndSale | -33.84M | -11.07M | -22.29M | -20.43M |
| PurchaseOfPPE | -33.84M | -11.07M | -22.29M | -20.43M |
| OperatingCashFlow | -302.41M | -352.98M | -361.82M | -292.76M |
| CashFlowFromContinuingOperatingActivities | -302.41M | -352.98M | -361.82M | -292.76M |
| ChangeInWorkingCapital | -24.27M | -127.02M | -6.52M | -2.89M |
| ChangeInOtherCurrentLiabilities | -10.90M | -12.07M | -10.79M | -1.94M |
| ChangeInPayablesAndAccruedExpense | 21.98M | 737.00K | 24.60M | 1.18M |
| ChangeInAccruedExpense | 28.64M | 8.58M | 19.77M | -4.70M |
| ChangeInPayable | -6.66M | -7.84M | 4.83M | 5.88M |
| ChangeInAccountPayable | -6.66M | -7.84M | 4.83M | 5.88M |
| ChangeInPrepaidAssets | -8.02M | -2.11M | -10.06M | -2.13M |
| ChangeInInventory | -14.21M | -44.38M | -10.12M | 0.00 |
| ChangeInReceivables | -13.11M | -69.19M | -149.00K | 0.00 |
| ChangesInAccountReceivables | -13.11M | -69.19M | -149.00K | 0.00 |
| StockBasedCompensation | 61.58M | 109.63M | 62.62M | 84.02M |
| ProvisionandWriteOffofAssets | 13.40M | |||
| AssetImpairmentCharge | 7.36M | 0.00 | 397.00K | 0.00 |
| AmortizationOfSecurities | -7.20M | -10.26M | -3.60M | 474.00K |
| DeferredTax | -2.07M | -2.83M | -3.48M | 0.00 |
| DeferredIncomeTax | -2.07M | -2.83M | -3.48M | 0.00 |
| DepreciationAmortizationDepletion | 47.32M | 48.07M | 33.13M | 21.14M |
| DepreciationAndAmortization | 47.32M | 48.07M | 33.13M | 21.14M |
| AmortizationCashFlow | 23.08M | 26.38M | 9.85M | 0.00 |
| AmortizationOfIntangibles | 23.08M | 26.38M | 9.85M | 0.00 |
| Depreciation | 24.25M | 21.69M | 23.28M | 21.14M |
| OperatingGainsLosses | -194.00K | 1.61M | 70.00K | |
| NetForeignCurrencyExchangeGainLoss | -238.00K | -175.00K | 70.00K | 0.00 |
| GainLossOnSaleOfPPE | 0.00 | -5.57M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -390.98M | -372.18M | -444.04M | -395.89M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IOVA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|